Ascendis Pharma A/S
Business
Ascendis Pharma A/S is a global biopharmaceutical company that develops long-acting therapies using its proprietary TransCon technology platform. Its main products and candidates include marketed endocrinology rare disease therapies YORVIPATH (palopegteriparatide) and SKYTROFA (lonapegsomatropin) and clinical-stage programs such as TransCon CNP (navepegritide) and TransCon IL-2 b/g. The company organizes its operations around Endocrinology Rare Disease, Oncology and technology collaborations/partnered commercialization efforts. It commercializes and distributes products primarily in the United States and Europe (direct country clusters), through specialty pharmacies, and via exclusive partners and licensees across over 75 international markets including strategic collaborations in Japan and Greater China.
Summary from filing dated 2026-02-11
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-228.03M |
| Total assets | $1.30B |
| Total liabilities | $1.47B |
| Stockholders' equity | — |
| Operating cash flow | — |